Top Story Today
The Cancer Vaccine That Actually Knows Your Name
For the first time ever, a personalized mRNA cancer vaccine has succeeded in a pivotal Phase 3 trial. Moderna and Merck's intismeran autogene, built by sequencing each patient's tumor and designing a custom vaccine targeting their unique mutations, hit both primary and secondary endpoints in surgically removed high-risk melanoma. Patients who received the vaccine alongside Keytruda stayed cancer-free significantly longer and saw delayed distant spread compared to Keytruda alone. Full numerical results and overall survival data are still pending, but the signal is strong enough to put the entire oncology world on notice.
Why it matters: This is the first time an individualized neoantigen vaccine has succeeded at this scale, potentially opening an entirely new treatment paradigm for solid tumors and validating mRNA technology's post-COVID future in oncology.
Read more →Deals and M&A
J&J Drops $785 Million for the Right to Kill the CAR-T Factory
Johnson & Johnson committed $785 million in total initial payments—including an equity investment and development milestones—for an exclusive option to acquire Sail Biomedicines and its in vivo CAR-T platform, with a separate acquisition price of $2.58 billion if the option is exercised. Sail's technology uses nanoparticles to reprogram T cells inside the patient's body, skipping the weeks-long, $400,000-per-dose manufacturing process that plagues current cell therapies. J&J joins AbbVie, AstraZeneca, and Gilead in a land grab for factory-free cell therapy.
Read more →Roche's $2.3 Billion Answer to the Muscle Problem Plaguing Ozempic
Up to a third of weight lost on GLP-1 drugs isn't fat; it's muscle. Roche just licensed Hanmi's HM17321, a Phase 1 drug that works through a completely different mechanism (the CRF2 receptor) to burn fat while preserving lean mass. The deal: $190 million upfront, up to $2.3 billion total. It's bold, unproven in humans, and exactly the kind of differentiated bet Roche needs to catch Novo and Lilly.
Read more →Clinical and Regulatory
Lilly's Oral Weight-Loss Pill Lands in Europe, No Needle Required
Eli Lilly launched Foundayo (orforglipron), the first oral GLP-1 weight-loss pill in Europe, through private prescriptions in the UK. It beat Novo Nordisk's oral semaglutide head-to-head, delivering roughly 74% greater weight loss, with no food or water restrictions. When Novo launched its oral Wegovy, 36% of prescriptions went to patients who had never tried a GLP-1 before. Pills aren't just replacing needles; they're expanding the entire market.
Read more →LEQEMBI Ditches the IV Pole With New At-Home Autoinjector
The FDA approved a subcutaneous autoinjector version of LEQEMBI, converting the Alzheimer's antibody from biweekly IV infusions into a more convenient weekly at-home shot. Drug exposure matched the IV version at 104%. Patients still need periodic MRI monitoring for brain swelling risks, but the biggest logistical barrier to adoption just got a lot smaller.
Read more →The Gene Therapy That Wants to Replace Your Midnight Cornstarch Alarm
Patients with GSDIa wake up multiple times a night to eat raw cornstarch or risk a blood sugar crash. Ultragenyx's gene therapy DTX401 cut that dependence by 61% over 96 weeks in trials, and the FDA was set to decide on approval August 23. If greenlit, it becomes the first AAV gene therapy for a rare metabolic liver disease, a signal moment for the entire field.
Read more →Regenxbio's Brain Tumor Discovery Triggers FDA Clinical Hold
Weeks before refiling its Hunter syndrome gene therapy, Regenxbio hit a wall. A brain tumor found in a child treated with a sibling program (for Hurler syndrome) triggered an FDA clinical hold on both programs. The suspected cause: the AAV vector may have inserted into DNA in a way that spurred abnormal cell growth. It's the latest safety scare in a field where roughly 60% of AAV-related clinical holds stem from adverse events or deaths.
Read more →Tempus Turns the Humble ECG Into a Pulmonary Hypertension Detector
Pulmonary hypertension affects up to 10% of people over 65, yet it's routinely missed for months or years. Tempus AI just won FDA clearance for software that scans standard 12-lead ECGs for hidden signs of the disease, no new hardware required. It's the company's third cardiac AI clearance, turning the most common heart test in medicine into a multi-disease screening tool.
Read more →Funding and Policy
A Two-Year-Old Heart Startup Just Raised $440 Million on Day One
Braveheart Bio, with zero approved products, priced its IPO at $18 per share and pulled in $440 million (with greenshoe) for a single cardiac myosin inhibitor targeting hypertrophic cardiomyopathy. It headlined a billion-dollar week of biotech IPOs, with 2026 now tracking $6.5 billion in total proceeds across 21 offerings. Investors are writing big checks again, but only for proven teams and validated mechanisms.
Read more →The UK Bets $335 Million It Can Out-Science Everyone Post-Brexit
The UK government earmarked 250 million pounds for a massive biosecurity campus in Essex, part of a 2 billion-plus pound life sciences spending blitz. The country is also investing 600 million pounds in NHS health data access and 520 million pounds in manufacturing. With zero UK biotech IPOs in 2025, though, the real question is whether government money can fix a capital markets problem.
Read more →